When Should a Mouth Ulcer Be Biopsied?

1. What is the practical threshold for biopsy?

Duration matters, but clinical suspicion takes priority. A recently noticed ulcer with a firm base, fixation to deeper tissue, or an associated neck mass should not enter a routine observation period.

A brief, documented review interval may be reasonable when there is a convincing reversible cause and no suspicious feature. Persistence after that cause is addressed, recurrence at the same site, or an uncertain diagnosis changes the decision.

The two-week threshold is a safety-net trigger, not a diagnostic test. It does not mean every ulcer present for 15 days is malignant, or that a lesion present for fewer days is safe.

• ·Prompt biopsy or referral: induration, meaning abnormal firmness; fixation; irregular or raised margins; unexplained bleeding; or an associated red or white patch.
• ·In-person examination: any ulcer that has not healed beyond two weeks, even when painless.
• ·Urgent assessment: a lump, numbness, difficulty opening the mouth, difficulty swallowing, or suspicious neck nodes.
• ·Emergency assessment: airway compromise, inability to swallow fluids, rapidly progressive swelling, or uncontrolled bleeding.

2. What do established guidelines actually say?

The American Dental Association's 2017 evidence-based guideline on evaluating potentially malignant disorders in the oral cavity supports immediate biopsy or specialist referral for a clinically suspicious lesion. Potentially malignant disorders are conditions associated with an increased risk of oral cancer. The guideline also supports follow-up of apparently innocuous lesions, with biopsy or referral when they persist and a potentially malignant disorder cannot be excluded.

NICE guideline NG12, Suspected cancer: recognition and referral, advises considering a suspected cancer pathway referral for unexplained oral ulceration lasting more than three weeks. That is a UK referral criterion, not a rule requiring clinicians to wait three weeks before investigating suspicious findings.

These recommendations support a risk-based approach rather than a duration-only rule. In India, the referral route depends on local services, but administrative arrangements should not delay assessment of a suspicious ulcer.

• ·Use two weeks as a practical reassessment and escalation threshold for an unhealed ulcer.
• ·Do not present the two-week threshold as the exact wording of NICE NG12.
• ·Light-based devices, stains and cytology, which examines shed or sampled cells, do not replace tissue biopsy when cancer is suspected.

3. What differential diagnosis should be considered?

The differential diagnosis should reflect duration, distribution, recurrence, immune status and associated findings. A solitary persistent ulcer raises different concerns from repeated episodes of multiple ulcers that heal completely between attacks.

Clinical appearance alone may not distinguish inflammation, infection and malignancy. A plausible traumatic source can coexist with cancer and should not end the assessment.

• ·Mechanical or chemical injury: a sharp tooth, unstable denture, habitual biting, or an identifiable contact exposure. The lesion should fit the exposure anatomically and improve after it is addressed.
• ·Recurrent aphthous stomatitis: repeated episodes of painful, non-infectious ulcers, usually on movable lining mucosa. New, unusually persistent or atypical lesions need reassessment.
• ·Malignancy: oral squamous cell carcinoma, a cancer arising from surface lining cells; lymphoma, a cancer of immune cells; or less commonly a salivary gland malignancy.
• ·Infection: viral, bacterial or fungal disease, including tuberculosis or syphilis when the history and examination support investigation.
• ·Immune-mediated disease: erosive lichen planus or blistering disorders, where immune activity damages the oral lining.
• ·Systemic disease: blood disorders, nutritional deficiency, inflammatory bowel disease or Behçet disease, a condition that can cause recurrent oral and genital ulcers with eye or other inflammation.
• ·Medication-related injury and ulcers associated with immunosuppression, meaning reduced immune defence.

4. What history changes the biopsy decision?

Establish whether this is one continuously present ulcer or repeated ulcers in approximately the same area. Ask when the lesion was first noticed, whether it ever fully healed, and whether its size or character has changed.

Pain is not a reliable discriminator. Early cancer may be painless, while benign inflammatory ulcers can be very painful.

• ·Local history: recent dental treatment, denture use, biting, sharp teeth, burns and other contact injury.
• ·Risk exposures: smoked or smokeless tobacco, areca nut or supari, alcohol, and previous head and neck cancer or radiotherapy.
• ·Associated symptoms: bleeding, altered sensation, referred ear pain, weight loss, swallowing difficulty, voice change or reduced mouth opening.
• ·Systemic context: fever, gastrointestinal symptoms, skin lesions, genital ulcers, eye symptoms and recurrent infections.
• ·Medication and immune history: recent medication changes, cancer treatment, transplant history, HIV status where known, and immune-suppressing treatment.
• ·Procedural considerations: bleeding history, medicines affecting clotting, allergies, relevant comorbidity and previous biopsy reports.

5. What is a useful examination sequence?

Start with general appearance and immediate safety concerns, then examine the face and neck. A neck lump may be an important presenting feature even when the oral lesion is small.

Examine the whole oral cavity under adequate illumination rather than focusing only on the reported ulcer. Record findings sufficiently clearly that another clinician can judge change at review.

• ·Assess facial asymmetry, swelling, mouth opening, voice and ability to handle saliva.
• ·Examine the cervical lymph nodes, meaning lymph nodes in the neck, noting site, size, tenderness, firmness and mobility.
• ·Inspect the lips, cheeks, gums, palate, floor of mouth and all accessible tongue surfaces, including the lateral and undersurfaces.
• ·Document the ulcer's exact site, dimensions, number, margins, surface, surrounding colour and relationship to teeth or appliances.
• ·Assess firmness, fixation, depth and associated submucosal swelling, meaning swelling beneath the lining.
• ·Check relevant sensation and tongue movement when symptoms or lesion location suggest nerve or muscle involvement.
• ·Use consented clinical photographs with a scale where feasible. A photograph cannot establish tissue firmness or exclude deeper disease.

6. When are blood tests, microbiology or imaging useful?

Investigations should answer a specific clinical question. They should not become a sequence of tests that postpones tissue diagnosis in a suspicious lesion.

A blood count and targeted deficiency tests may help when ulcers are recurrent, extensive or accompanied by systemic symptoms. Infection testing should follow the clinical context; a positive surface swab may represent colonisation rather than the cause of a persistent ulcer.

Imaging is not routinely necessary before biopsy of a small, accessible superficial ulcer. Normal imaging cannot exclude an early surface cancer.

• ·Dental radiographs: suspected dental infection, adjacent bony disease or a possible tooth-related source.
• ·Contrast-enhanced computed tomography, or CT, and magnetic resonance imaging, or MRI: suspected deep extension, bone involvement, a deep mass or cancer staging, usually coordinated with the specialist team.
• ·Neck ultrasound with needle sampling: assessment of suspicious lymph nodes through an appropriate service.
• ·Imaging before tissue sampling: a pulsatile or strongly vascular-appearing lesion, where biopsy may carry substantial bleeding risk.
• ·Systemic investigations: selected according to the suspected inflammatory, infectious or blood disorder, rather than a universal ulcer panel.

7. When should biopsy be performed, and which type is appropriate?

Biopsy means removing tissue for laboratory examination. Histopathology is microscopic examination of that tissue to identify disease and assess its architecture.

A suspicious ulcer usually requires an incisional biopsy, which samples part of the lesion, rather than an unplanned complete removal. The choice depends on size, site, likely diagnosis, access and the clinician's training.

Excisional biopsy removes the whole lesion and may suit selected small, clinically benign lesions. When malignancy is possible, specialist planning helps preserve anatomical information and avoid complicating definitive treatment.

• ·Proceed toward tissue diagnosis when suspicion is present at the first visit; observation is not required.
• ·Consider biopsy or referral when a persistent ulcer remains unexplained or fails to resolve after an apparently causal irritant is addressed.
• ·Do not routinely biopsy every episode of a typical, fully resolving recurrent ulcer pattern.
• ·Seek specialist input for large, heterogeneous, deeply fixed or difficult-to-access lesions, and for lesions near important anatomical structures.
• ·Account for bleeding risk, medical stability and specimen-handling capability without allowing avoidable delay.

8. What makes a biopsy diagnostically useful?

A biopsy must represent the suspected disease. A sample consisting only of surface debris or dead tissue can produce a non-specific report without resolving the clinical concern.

Site selection, tissue depth and preservation matter, especially when invasion beneath the lining is suspected. Large lesions with different appearances may need more than one representative sample, planned by the treating clinician or specialist.

The pathology request should communicate the clinical question, not simply say “ulcer”. Clinical photographs or a site diagram can help where secure local systems permit.

• ·Useful request details include duration, exact site, dimensions, risk factors, associated firmness or nodes, and the working differential diagnosis.
• ·For suspected blistering disease, direct immunofluorescence may be needed. This test detects immune deposits in tissue and commonly requires a separate specimen from tissue near the lesion.
• ·Specimens for immunofluorescence, microbiology or suspected lymphoma may need handling different from routine histology; laboratory coordination is important before sampling.
• ·A non-specific pathology report must be interpreted alongside the examination. It is not automatic reassurance when the lesion remains suspicious.

9. When should the patient be referred, and to whom?

Urgent referral is appropriate when oral cancer is suspected, when local biopsy would be unsafe or delayed, or when the lesion requires specialist sampling. Oral medicine, oral and maxillofacial surgery, or a head and neck cancer service may be the appropriate entry point.

Oral medicine assessment is particularly useful for complex ulceration, suspected immune-mediated disease and clinicopathological disagreement. Suspected systemic disease may require coordinated physician, dermatology, gastroenterology or infectious disease assessment.

For clinicians in Mumbai, Thane, Ambarnath, Badlapur and Ulhasnagar, referral should prioritise timely access to examination, pathology and onward cancer care. A remote discussion can assist coordination but cannot replace palpation or biopsy.

• ·Include the duration, examination findings, photographs where available, relevant exposures and previous investigation results.
• ·State explicitly when cancer is suspected and identify red flags.
• ·Confirm who will arrange the appointment, track attendance and act on the pathology result.
• ·Use emergency services rather than routine referral for airway compromise, uncontrolled bleeding or inability to maintain hydration.

10. What if the ulcer persists despite a benign biopsy result?

Clinical and pathological findings must agree. A report of non-specific inflammation does not adequately explain a progressively indurated, fixed or enlarging ulcer.

Persistent concern warrants communication with the pathologist and specialist reassessment. Depending on the findings, this may lead to slide review, further tissue sampling, additional laboratory studies or imaging.

Sampling error is one explanation for disagreement, but it is not the only one. Infection, immune-mediated disease, continued injury and conditions beneath the surface may require a revised assessment.

• ·Check that the sampled site matches the clinically concerning area.
• ·Review whether the specimen was representative and adequate for the question asked.
• ·Compare current measurements and photographs with baseline findings.
• ·Escalate new numbness, a lump, unexplained bleeding, reduced mouth opening or swallowing difficulty regardless of the earlier report.
• ·Maintain follow-up until healing, a satisfactory diagnosis or documented transfer of care.

11. How should observation and safety-netting be documented?

Observation is an active clinical decision, not an open-ended instruction to return if worried. The record should explain why immediate biopsy was not chosen and specify the review date and escalation plan.

At review, distinguish symptom improvement from complete mucosal healing. Less pain does not establish resolution, and repeated empirical treatment should not substitute for reassessment of an unexplained persistent ulcer.

Explain uncertainty without prematurely labelling the lesion as cancer or harmless. Biopsy is a diagnostic investigation, and many biopsied lesions prove non-malignant.

• ·Record the provisional explanation, objective findings and any causal factor addressed.
• ·Give a clear review interval; an ulcer already present beyond two weeks needs assessment rather than a fresh automatic waiting period.
• ·Document advice about earlier review for enlargement, a lump, numbness, unexplained bleeding, or difficulty opening the mouth or swallowing.
• ·Track missed appointments and outstanding pathology according to local clinical governance procedures.